Top

Current Treatment Options in Gastroenterology

Published in:

01-06-2021 | Endoscopy | Endoscopy (P Siersema, Section Editor)

Screening for Barrett’s Oesophagus: Are We Ready for it?

Authors: Aisha Yusuf, PhD (cand.), Rebecca C. Fitzgerald, MD, FRCP, FMedSci

Published in: Current Treatment Options in Gastroenterology | Issue 2/2021

Abstract

Purpose of review

The targeted approach adopted for Barrett’s oesophagus (BO) screening is sub-optimal considering the large proportion of BO cases that are currently missed. We reviewed the literature highlighting recent technological advancements in efforts to counteract this challenge. We also provided insights into strategies that can improve the outcomes from current BO screening practises.

Recent findings

The standard method for BO detection, endoscopy, is invasive and expensive and therefore inappropriate for mass screening. On the other hand, endoscopy is more cost-effective for screening a high-risk population. A consensus has however not been reached on who should be screened. Risk prediction algorithms have been tested as an enrichment pre-screening tool reporting modest AUC’s but require more prospective evaluation studies. Less invasive endoscopy methods like trans-nasal endoscopy, oesophageal capsule endsocopy and non-endoscopic cell collection devices like the Cytosponge coupled with biomarker analysis have shown promise in BO detection with randomised clinical trial evidence.

Summary

A three-tier precision cancer programme whereby risk prediction algorithms and non-endoscopic minimally invasive cell collection devices are used to triage test a wider pool of individuals may improve the detection rate of current screening practises with minimal cost implications.

Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the oesophagus in england and wales up to 2001. Br J Cancer. 2008;99(Suppl 1):S11–3.PubMedPubMedCentral

di Pietro M, Fitzgerald RC. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett’s oesophagus with low-grade dysplasia. Gut. 2018;67(2):392–3.PubMed

Falk GW. Barrett’s esophagus. Gastroenterology. 2002;122(6):1569–91.PubMed

Curvers WL, Ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–30.PubMed

Wani S, Puli SR, Shaheen NJ, Westhoff B, Slehria S, Bansal A, et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol. 2009;104(2):502–13.PubMed

Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.PubMed

Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67(3):394–8.PubMed

Verbeek RE, Leenders M, Ten Kate FJW, Van Hillegersberg R, Vleggaar FP, Van Baal JWPM, et al. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109(8):1215–22 Available from: https://doi.org/10.1038/ajg.2014.156.PubMed

9.••

Tan MC, Mansour N, White DL, Sisson A, El-Serag HB, Thrift AP. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett’s oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020;52(1):20–36 This is a recent systematic review and meta-analysis of relevant papers from the past 10 years which highlighted the significant number of BO cases missed by current screening practises.

10.

Dulai GS, Gornbein J, Kahn KL, Guha S, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.PubMed

11.

Cooper SC, El-Agib A, Dar S, Mohammed I, Nightingale P, Murray IA, et al. Endoscopic surveillance for Barrett’s oesophagus: the patients’ perspective. Eur J Gastroenterol Hepatol. 2009;21:850–4.PubMed

12.

Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049–57.PubMedPubMedCentral

13.

Kim NJ-E, Vásquezc VB, Elizabeth Torrese RM, Nicola B. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015;176(3):139–48.

14.

Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50. https://doi.org/10.1038/ajg.2015.322.CrossRefPubMed

15.

Gastroenterological Association; Spechler SJ, Sharma P et al. American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011 140(3):1084-1091.

16.

Fitzgerald RC, Di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.PubMed

17.

Weusten BLAM, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau JM, Esteban JM, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49(2):191–8.PubMed

18.

Whiteman DC, Appleyard M, Bahin FF, Bobryshev YV, Bourke MJ, Brown I, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterology Hepatol. 2015;30:804–20.

19.

Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, et al. Determining risk of Barrett’s esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. Gastroenterology. 2018;154(5):1273–1281.e3.PubMed

20.

Smith RRL, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am J Surg Pathol. 1984;8:563–73.PubMed

21.

Chak A, Faulx A, Eng C, Grady W, Kinnard M, Ochs-Balcom H, et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer. 2006;107(9):2160–6.PubMed

22.

Weijenborg PW, Smout AJPM, Krishnadath KK, Bergman JGHM, Verheij J, Bredenoord AJ. Esophageal sensitivity to acid in patients with Barrett’s esophagus is not related to preserved esophageal mucosal integrity. Neurogastroenterol Motil. 2017;29(7):1–6.

23.

Vaughan TL, Fitzgerald RC, Hutchinson F. Precision cancer prevention of esophageal adenocarcinoma: a lesson from Napoleon. Nat Rev Gastroenterol Hepatol. 2015;12(4):243–8.PubMedPubMedCentral

24.

Juhasz A, Sundaram A, Hoshino M, Lee TH, Filipi CJ, Mittal SK. Endoscopic assessment of failed fundoplication: a case for standardization. Surg Endosc. 2011;25:3761–6.PubMed

25.

Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33:306–9.PubMed

26.

Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, et al. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol. 2012;107:1655–61.PubMed

27.

Rubenstein JH, Thrift AP. Risk factors and populations at risk: selection of patients for screening for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29(1):41–50. https://doi.org/10.1016/j.bpg.2014.11.009.CrossRefPubMed

28.

Baldwin-hunter BL, Knotts RM, Leeds SD, Rubenstein JH, Lightdale CJ, Abrams JA. Use of the electronic health record to target patients for non- endoscopic Barrett’s esophagus screening. Dig Dis Sci. 2020;64(12):3463–70.

29.

Thrift AP, Vaughan TL, Anderson LA, Whiteman DC, El-Serag HB. External validation of the Michigan Barrett’s esophagus prediction tool. Clin Gastroenterol Hepatol. 2017;15(7):1124–6.PubMedPubMedCentral

30.•

Rosenfeld A, Graham DG, Jevons S, Ariza J, Hagan D, Wilson A, et al. Development and validation of a risk prediction model to diagnose Barrett’s oesophagus (MARK-BE): a case-control machine learning approach. Lancet Digit Health. 2020;2(1):e37–48 Majority of BO risk predictions alogorthims developed thus far have reported AUCs ranging from 0.61 to 0.75. The model in this study (MARK-BE) demonstrated an AUC of 0.81 having carried out training and validation in large independent data sets.

31.

Moriarty JP, Shah ND, Rubenstein JH, Blevins CH, Johnson M, Katzka DA, et al. Costs associated with Barrett’s esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointest Endosc. 2018;87:88–94.e2.PubMed

32.

Palmer KR. Complications of gastrointestinal endoscopy. Gut. 2007;56:456–7.PubMedPubMedCentral

33.

Peery AF, Hoppo T, Garman KS, Dellon ES, Daugherty N, Bream S, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:945–953.e2.PubMedPubMedCentral

34.

Wilkins T, Gillies RA. Office-based ultrathin esophagogastroduodenoscopy in a primary care setting. J Am Board Fam Pract. 2004;17:438–42.PubMed

35.

Cho S, Arya N, Swan K, Cirocco M, Kandel G, Kortan P, et al. Unsedated transnasal endoscopy: a Canadian experience in daily practice. Can J Gastroenterol. 2008;22:243–6.PubMedPubMedCentral

36.

Sami SS, Dunagan KT, Johnson ML, Schleck CD, Shah ND, Zinsmeister AR, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol. 2015;110(1):148–58.PubMed

37.

Shariff MK, Bird-Lieberman EL, O’Donovan M, Abdullahi Z, Liu X, Blazeby J, et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc. 2012;75(5):954–61. Available from:. https://doi.org/10.1016/j.gie.2012.01.029.CrossRefPubMed

38.

Sami SS, Subramanian V, Ortiz-Fernández-Sordo J, Saeed A, Singh S, Guha IN, et al. Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis. Gastrointest Endosc. 2015;82:782–92.PubMed

39.

Sami SS, Iyer PG, Pophali P, Halland M, di Pietro M, Ortiz-Fernandez-Sordo J, et al. Acceptability, accuracy, and safety of disposable transnasal capsule endoscopy for Barrett’s esophagus screening. Clin Gastroenterol Hepatol. 2019;17:638–646.e1.PubMed

40.

Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett’s esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009;104(6):1533–9. https://doi.org/10.1038/ajg.2009.86.CrossRefPubMed

41.

Song J, Bai T, Zhang L, Xiang XL, Xie XP, Hou XH. Better view by detachable string magnetically controlled capsule endoscopy for esophageal observation: a retrospective comparative study. Dis Esophagus. 2020;33:doz104.PubMed

42.

Yun SH, Tearney GJ, Vakoc BJ, Shishkov M, Oh WY, Desjardins AE, et al. Comprehensive volumetric optical microscopy in vivo. Nat Med. 2006;12(12):1429–33.PubMedPubMedCentral

43.

Gora MJ, Sauk JS, Carruth RW, Gallagher KA, Suter MJ, Nishioka NS, et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med. 2013;19(2):238–40.PubMedPubMedCentral

44.

Gora MJ, Simmons LH, Quénéhervé L, Grant CN, Carruth RW, Lu W, et al. Tethered capsule endomicroscopy: from bench to bedside at a primary care practice. J Biomed Opt. 2016;21(10):104001.PubMedPubMedCentral

45.

Gehrung M, Crispin-Ortuzar M, Berman AG, O’donovan M, Fitzgerald RC, Markowetz F. Triage-driven diagnosis for early detection of esophageal cancer 2 using deep learning. medRxiv. 2020;2020:07.16.20154732 https://www.medrxiv.org/content/10.1101/2020.07.16.20154732v1.

46.

Paterson AL, Gehrung M, Fitzgerald RC, O’Donovan M. Role of TFF3 as an adjunct in the diagnosis of Barrett’s esophagus using a minimally invasive esophageal sampling device—the CytospongeTM. Diagn Cytopathol. 2020;48(3):253–64.PubMed

47.

Iyer PG, Taylor WR, Johnson ML, Lansing RL, Maixner KA, Hemminger LL, et al. Accurate nonendoscopic detection of Barrett’s esophagus by methylated DNA markers: a multisite case control study. Am J Gastroenterol. 2020;115:1201–9.PubMedPubMedCentral

48.

Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med. 2018;10(424):eaao5848.PubMedPubMedCentral

49.

Januszewicz W, Tan WK, Lehovsky K, Debiram-Beecham I, Nuckcheddy T, Moist S, et al. Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients. Clin Gastroenterol Hepatol. 2019;17(4):647–656.e1. https://doi.org/10.1016/j.cgh.2018.07.043.CrossRefPubMed

50.••

Fitzgerald RC, di Pietro M, O’Donovan M, Maroni R, Muldrew B, Debiram-Beecham I, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet. 2020;396(10247):333–44 The first randomized trial to evaluate the true impact of a non-endoscopic cell collection device screening strategy in a primary care setting with >13000 study participants.

51.

Kadri PSR, Lao-Sirieix I, O’Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: Cohort study. BMJ. 2010;341(7773):595.

52.

Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, et al. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(1):23–31. Available from:. https://doi.org/10.1016/S2468-1253(16)30118-2.CrossRefPubMed

53.

Chettouh H, Mowforth O, Galeano-Dalmau N, Bezawada N, Ross-Innes C, Macrae S, et al. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut. 2018;67(11):1942–9.PubMed

54.

Katz-Summercorn A, Anand S, Ingledew S, Huang Y, Roberts T, Galeano-Dalmau N, et al. Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett’s oesophagus. J Pathol Clin Res. 2017;3(4):258–67.PubMedPubMedCentral

55.

Li X, Kleeman S, Coburn SB, Fumagalli C, Perner J, Jammula S, et al. Selection and application of tissue microRNAs for nonendoscopic diagnosis of Barrett’s esophagus. Gastroenterology. 2018;155(3):771–783.e3. https://doi.org/10.1053/j.gastro.2018.05.050.CrossRefPubMedPubMedCentral

56.

Paterson AL, Lao-Sirieix P, O’Donovan M, Debiram-Beecham I, di Pietro M, Miremadi A, et al. Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. Histopathology. 2017;70(2):203–10.PubMed

57.

Song L, Jia J, Peng X, Xiao W, Li Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis. Sci Rep. 2017;7(1):3032.PubMedPubMedCentral

58.

Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case–control study. PLoS Med. 2015;12(1):1–19.

59.

Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, et al. Cost effectiveness of screening patients with gastroesophageal reflux disease for Barrett’s esophagus with a minimally invasive cell sampling device. Clin Gastroenterol Hepatol. 2017;15(9):1397–1404.e7. https://doi.org/10.1016/j.cgh.2017.02.017.CrossRefPubMedPubMedCentral

60.

Iqbal U, Siddique O, Ovalle A, Anwar H, Moss SF. Safety and efficacy of a minimally invasive cell sampling device (‘Cytosponge’) in the diagnosis of esophageal pathology: a systematic review. Eur J Gastroenterol Hepatol. 2018;30(11):1261–9.PubMed

61.

Iyer PG, Taylor WR, Johnson ML, Lansing RL, Maixner KA, Yab TC, et al. Highly discriminant methylated DNA markers for the non-endoscopic detection of Barrett’s esophagus. Am J Gastroenterol. 2018;113(8):1156–66.PubMed

62.

Kisiel JB, Dukek BA, RVSR K, Ghoz HM, Yab TC, Berger CK, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, Phase I Pilot, and Phase II clinical validation. Hepatology. 2019;69(3):1180–92.PubMedPubMedCentral

63.

Chandar AK, Alaber O, Dumot JA, Faulx AL, Brock W, Thota PN, et al. Mo1170 Modifications in non-endoscopic distal esophagus sampling devices improve ability to swallow and DNA yield. Gastrointest Endosc. 2019;89:AB448.

64.

Clark RJ, Craig MP, Agrawal S, Kadakia M. microRNA involvement in the onset and progression of Barrett’s esophagus: a systematic review. Oncotarget. 2018;9(8):8179–96.PubMedPubMedCentral

65.

Bus P, Kestens C, Ten Kate FJW, Peters W, Drenth JPH, Roodhart JML, et al. Profiling of circulating microRNAs in patients with Barrett’s esophagus and esophageal adenocarcinoma. J Gastroenterol. 2016;51(6):560–70.PubMed

66.

Cabibi D, Caruso S, Bazan V, Castiglia M, Bronte G, Ingrao S, et al. Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget. 2016;7(30):47821–30.PubMedPubMedCentral

67.

Wang L, Ji F, Liu G, Wang W, Li Z, Yue Y, et al. Upregulation of circulating mir130a is correlated with development of Barrett’s esophagus and esophageal adenocarcinoma. Onco Targets Ther. 2019;12:1–7.PubMed

68.

Pavlov K, Kluiver J, Meijer C, Boersma-van Ek W, Kruyt FAE, Karrenbeld A, et al. Circulating miRNAs in patients with Barrett’s esophagus, high-grade dysplasia and esophageal adenocarcinoma. J Gastrointest Oncol. 2018;9(6):1150–6.PubMedPubMedCentral

69.

Craig MP, Rajakaruna S, Paliy O, Sajjad M, Madhavan S, Reddy N, et al. Differential MicroRNA signatures in the pathogenesis of Barrett’s esophagus. Clin Transl Gastroenterol. 2020;11(1):e00125.PubMedPubMedCentral

70.

Ofman JJ, Hall MP, Aravanis AM, Park M. GRAIL and the quest for earlier multi-cancer detection. Nature. 2018

71.

Krilaviciute A, Heiss JA, Leja M, Kupcinskas J, Haick H, Brenner H. Detection of cancer through exhaled breath: a systematic review. Oncotarget. 2015;6:38643–57.PubMedPubMedCentral

72.

Hanna GB, Boshier PR, Markar SR, Romano A. Accuracy and methodologic challenges of volatile organic compound-based exhaled breath tests for cancer diagnosis: a systematic review and meta-analysis. JAMA Oncol. 2019;5(1):1–11.

73.

Kumar S, Huang J, Abbassi-Ghadi N, HA MK, Veselkov KA, Hoare JM, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg. 2015;262(6):981–90.PubMed

74.

Markar SR, Wiggins T, Antonowicz S, Chin ST, Romano A, Nikolic K, et al. Assessment of a noninvasive exhaled breath test for the diagnosis of oesophagogastric cancer. JAMA Oncol. 2018;4(7):970–6.PubMedPubMedCentral

75.

Chan DK, Zakko L, Visrodia KH, Leggett CL, Lutzke LS, Clemens MA, et al. Breath testing for Barrett’s esophagus using exhaled volatile organic compound profiling with an electronic nose device. Gastroenterology. 2017;152(1):24–6.PubMed

76.

Peters Y, Schrauwen RWM, Tan AC, Bogers SK, De Jong B, Siersema PD. Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device. Gut. 2020;69(7):1169–72.PubMed

Title: Screening for Barrett’s Oesophagus: Are We Ready for it?
Authors: Aisha Yusuf, PhD (cand.)
Rebecca C. Fitzgerald, MD, FRCP, FMedSci
Publication date: 01-06-2021
Publisher: Springer US
Keyword: Endoscopy
Published in: Current Treatment Options in Gastroenterology / Issue 2/2021
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-021-00342-1

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2021

Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC)

Strategies to Improve Delivery of Cirrhosis Care

EUS-FNA vs EUS-FNB for Pancreatic Lesions: Which Needle When to Use?

Reproductive Health in IBD Patients

Prevention of Bleeding After Endoscopic Resection of Colonic Polyps: to Clip or not to Clip

Treatment of Micronutrient Deficiencies Pre and Post Bariatric Surgery

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage